JP2021523877A - Ｇｌｐ１ｒアゴニストの治療的使用 - Google Patents

Ｇｌｐ１ｒアゴニストの治療的使用 Download PDF

Info

Publication number
JP2021523877A
JP2021523877A JP2020544255A JP2020544255A JP2021523877A JP 2021523877 A JP2021523877 A JP 2021523877A JP 2020544255 A JP2020544255 A JP 2020544255A JP 2020544255 A JP2020544255 A JP 2020544255A JP 2021523877 A JP2021523877 A JP 2021523877A
Authority
JP
Japan
Prior art keywords
day
phenyl
glp1r
agonist
glp1r agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020544255A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523877A5 (https=
JPWO2019217165A5 (https=
Inventor
エル アール フリーマン ジェニファー
エル アール フリーマン ジェニファー
カルメン バルカルセ ロペス マリア
カルメン バルカルセ ロペス マリア
Original Assignee
ブイティーブイ・セラピューティクス・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブイティーブイ・セラピューティクス・エルエルシー filed Critical ブイティーブイ・セラピューティクス・エルエルシー
Publication of JP2021523877A publication Critical patent/JP2021523877A/ja
Publication of JP2021523877A5 publication Critical patent/JP2021523877A5/ja
Publication of JPWO2019217165A5 publication Critical patent/JPWO2019217165A5/ja
Priority to JP2024081189A priority Critical patent/JP2024112903A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020544255A 2018-05-08 2019-05-01 Ｇｌｐ１ｒアゴニストの治療的使用 Pending JP2021523877A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024081189A JP2024112903A (ja) 2018-05-08 2024-05-17 Ｇｌｐ１ｒアゴニストの治療的使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862668384P 2018-05-08 2018-05-08
US62/668,384 2018-05-08
PCT/US2019/030110 WO2019217165A1 (en) 2018-05-08 2019-05-01 Therapeutic uses of glp1r agonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024081189A Division JP2024112903A (ja) 2018-05-08 2024-05-17 Ｇｌｐ１ｒアゴニストの治療的使用

Publications (3)

Publication Number Publication Date
JP2021523877A true JP2021523877A (ja) 2021-09-09
JP2021523877A5 JP2021523877A5 (https=) 2022-05-17
JPWO2019217165A5 JPWO2019217165A5 (https=) 2022-05-17

Family

ID=66484210

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020544255A Pending JP2021523877A (ja) 2018-05-08 2019-05-01 Ｇｌｐ１ｒアゴニストの治療的使用
JP2024081189A Pending JP2024112903A (ja) 2018-05-08 2024-05-17 Ｇｌｐ１ｒアゴニストの治療的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024081189A Pending JP2024112903A (ja) 2018-05-08 2024-05-17 Ｇｌｐ１ｒアゴニストの治療的使用

Country Status (9)

Country Link
US (2) US20210023072A1 (https=)
EP (1) EP3790549A1 (https=)
JP (2) JP2021523877A (https=)
KR (2) KR20210005843A (https=)
AU (2) AU2019266114A1 (https=)
CA (1) CA3090823A1 (https=)
MX (1) MX2020008387A (https=)
SG (1) SG11202007966UA (https=)
WO (1) WO2019217165A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3157525A1 (en) 2019-10-25 2021-04-29 Gilead Sciences, Inc. Glp-1r modulating compounds
WO2021154796A1 (en) 2020-01-29 2021-08-05 Gilead Sciences, Inc. Glp-1r modulating compounds
US12459954B2 (en) 2020-04-01 2025-11-04 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Crystalline form a of GLP-1 receptor agonist and preparation method therefor
WO2021196951A1 (zh) * 2020-04-01 2021-10-07 杭州中美华东制药有限公司 Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法
TW202210486A (zh) * 2020-05-28 2022-03-16 中國大陸商杭州中美華東製藥有限公司 一種製備ｇｌｐ—１受體激動劑的方法
EP4213847A4 (en) * 2020-09-21 2024-12-04 vTv Therapeutics LLC AMORPHOUS FORM OF AN ISOQUINOLINE DERIVATIVE
EP4247804A1 (en) 2020-11-20 2023-09-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
WO2022192430A1 (en) 2021-03-11 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
EP4304711A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
PH12023552860A1 (en) 2021-04-21 2024-05-20 Gilead Sciences Inc Carboxy-benzimidazole glp-1r modulating compounds
KR102920994B1 (ko) 2024-05-20 2026-02-02 (주)인벤티지랩 오르포르글리포론 또는 이의 약학적으로 허용되는 염을 포함하는 마이크로 입자 및 이의 제조 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002534512A (ja) * 1999-01-15 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 非ペプチドｇｌｐ−１アゴニスト
WO2011031620A1 (en) * 2009-09-11 2011-03-17 Transtech Pharma, Inc. Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same
JP2015510947A (ja) * 2012-03-22 2015-04-13 トランステック・ファーマ，エルエルシー 小分子ｇｌｐ１ｒアゴニストのトリス（ヒドロキシメチル）アミノメタン塩ならびにその医薬組成物および使用
JP2016505039A (ja) * 2013-01-17 2016-02-18 ブイティーブイ・セラピューティクス・エルエルシー Ｇｌｐ１ｒアゴニストとメトホルミンの組合わせおよび２型糖尿病その他の障害の処置のためのその使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7727983B2 (en) 2008-03-07 2010-06-01 Transtech Pharma, Inc. Oxadiazoanthracene compounds for the treatment of diabetes
JP5755217B2 (ja) 2009-03-30 2015-07-29 トランステック・ファーマ，エルエルシー 置換アゾアントラセン誘導体、その医薬組成物とその使用の方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002534512A (ja) * 1999-01-15 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 非ペプチドｇｌｐ−１アゴニスト
WO2011031620A1 (en) * 2009-09-11 2011-03-17 Transtech Pharma, Inc. Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same
JP2015510947A (ja) * 2012-03-22 2015-04-13 トランステック・ファーマ，エルエルシー 小分子ｇｌｐ１ｒアゴニストのトリス（ヒドロキシメチル）アミノメタン塩ならびにその医薬組成物および使用
JP2016505039A (ja) * 2013-01-17 2016-02-18 ブイティーブイ・セラピューティクス・エルエルシー Ｇｌｐ１ｒアゴニストとメトホルミンの組合わせおよび２型糖尿病その他の障害の処置のためのその使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, vol. 48, JPN6023015052, 2013, pages 119 - 130, ISSN: 0005240819 *
DIABATES, vol. 63, no. 1, JPN6023015053, 2014, pages 41 - 42, ISSN: 0005240818 *
JAMA., vol. 318, no. 15, JPN6023015051, 2017, pages 1460 - 1470, ISSN: 0005038871 *

Also Published As

Publication number Publication date
KR20210005843A (ko) 2021-01-15
JP2024112903A (ja) 2024-08-21
SG11202007966UA (en) 2020-11-27
CA3090823A1 (en) 2019-11-14
TW202015683A (zh) 2020-05-01
KR20260036616A (ko) 2026-03-17
US20250325536A1 (en) 2025-10-23
AU2025201814A1 (en) 2025-04-03
EP3790549A1 (en) 2021-03-17
MX2020008387A (es) 2020-12-11
US20210023072A1 (en) 2021-01-28
AU2019266114A1 (en) 2020-08-27
WO2019217165A1 (en) 2019-11-14

Similar Documents

Publication Publication Date Title
JP2021523877A (ja) Ｇｌｐ１ｒアゴニストの治療的使用
CN115135305B (zh) 药物制剂
AU2022202506B2 (en) Treatment of post-bariatric hypoglycemia with GLP-1 antagonists
JP7584894B2 (ja) エキセンディン（９－３９）の緩衝製剤
CN112512633A (zh) 使用gip/glp1共激动剂用于治疗的方法
AU2014207748B2 (en) Combinations of a GLP1R agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders
CN120513087A (zh) 用于肥胖症和其他疾病的组合疗法和轮换组合疗法
CN104582701B (zh) 减轻体重的方法
TW202529797A (zh) Ｇｌｐ－１類似物治療代謝疾病的方法及醫藥用途
TW202535453A (zh) 包含艾派那肽的醫藥組成物及其給藥方案
DK202530540A1 (en) Semaglutide in medical therapy including weight management
CN121969358A (zh) 选择性雄激素受体调节剂（sarm）化合物在长期体重管理中的用途
CN1976696A (zh) 用于预防或治疗脂质代谢异常的医药组合物
Mattoo et al. Exenatide: A Review of Pharmacology and Therapeutic Uses
HK1210424B (zh) Glp1r 激动剂和二甲双胍的组合及其在制备治疗 2 型糖尿病和其他障碍的药物中的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230418

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20230613

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230620

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231018

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240118